Condition
Metastatic Cutaneous Melanoma clinical trials and research
Research outlook What's coming for Melanoma: the next 6 months to 5 yearsAs of November 12, 2026, Find a Trial lists 6 Metastatic Cutaneous Melanoma clinical trials that are recruiting, at sites in 3 countries (most in United States (4), Russia (1), China (1)). By phase: Phase 2 (4), Phase 1 (1), Phase 1/2 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 6Clinical trials
- 3Countries
Newest Metastatic Cutaneous Melanoma clinical trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| Dual-target CSPG4/GD2 CAR-NK Cells for Advanced Melanoma | Phase 1/2 | Shenzhen, Guangdong | Recruiting | Jun 4, 2026 |
| Time-of-day immunotherapy for advanced melanoma | Phase 2 | Atlanta, Georgia and 1 other locations | Recruiting | Sep 4, 2025 |
| Anti-PD-1/PD-L1 with bevacizumab and low-dose cyclophosphamide for metastatic NSCLC and cutaneous melanoma after prior checkpoint therapy | Phase 2 | Saint Petersburg, Sankt-Peterburg | Recruiting | Aug 19, 2025 |
| Comparing home and clinic administration of nivolumab for cancer treatment | Phase 2 | Jacksonville, Florida | Recruiting | Feb 20, 2024 |
| Personalized vaccine treatment for advanced melanoma, breast cancer, and lung cancer | Phase 1 | Seattle, Washington | Recruiting | Oct 28, 2021 |
| Comparing two treatment combinations for melanoma with brain metastases | Phase 2 | Birmingham, Alabama and 330 other locations | Recruiting | Aug 12, 2020 |
All recruiting trials (6)
-
Dual-target CSPG4/GD2 CAR-NK Cells for Advanced Melanoma
This study tests a donor-derived CAR-NK cell therapy that targets CSPG4 or GD2 in adults with unresectable or metastatic melanoma after standard treatments.
-
Time-of-day immunotherapy for advanced melanoma
This trial tests whether giving the immune drugs ipilimumab and nivolumab in the morning rather than later in the day helps people with unresectable or metastatic melanoma respond better.
-
Anti-PD-1/PD-L1 with bevacizumab and low-dose cyclophosphamide for metastatic NSCLC and cutaneous melanoma after prior checkpoint therapy
We will try giving anti-PD-1/PD-L1 drugs together with bevacizumab and continuous low-dose cyclophosphamide to people with metastatic NSCLC or cutaneous melanoma whose cancer progressed after prior immune checkpoint treatment.
-
Comparing home and clinic administration of nivolumab for cancer treatment
This study tests whether giving cancer patients their treatment at home instead of in a clinic makes them feel better and prefer their care more.
-
Personalized vaccine treatment for advanced melanoma, breast cancer, and lung cancer
This study is testing a personalized vaccine combined with a treatment called nivolumab to see if it can help people with advanced melanoma, breast cancer, or lung cancer fight their tumors better.
-
Comparing two treatment combinations for melanoma with brain metastases
This study is testing two different treatment combinations for patients with melanoma that has spread to the brain to see which one helps them live longer without the disease getting worse.
Related topics
Quick answers
How many Metastatic Cutaneous Melanoma clinical trials are recruiting right now?
6, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 3 countries. The most sites are in United States (4 trials), Russia (1 trial), China (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 2: 4, Phase 1: 1, Phase 1/2: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.